查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1623069

抗血友病因子藥物的全球市場規模:各產品，各用途，各地區，範圍及預測

Global Antihemophilic Factor Drug Market Size By Product (250 IU, 500 IU, 1000 IU, 1500 IU), By Application (Adult, Pediatric), By Geographic Scope and Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

抗血友病因子藥物的市場規模及預測

抗血友病因子藥物的市場規模近年來一直以顯著的速度快速增長，預計在市場估計和預測期（2021-2028 年）內將顯著增長。

抗血友病因子藥物用於治療和控制出血性疾病患者的嚴重出血事件。人們認識的提高和全球人口中罕見疾病的增加是醫療保健行業面臨的關鍵問題，這推動了抗血友病因子藥物市場的成長。全球抗血友病因子藥物市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球抗血友病因子藥物市場

抗血友病因子藥物用於減緩和預防血液凝血因子 VIII 水平低下（血友病 A）患者的出血發作。它也可用於手術前的止血。凝血因子 VIII 水平正常的人，由於體內存在凝血因子 VIII（又稱抗血友病因子），因此在受傷、手術和凝血因子 VIII 出血後出現出血的風險會增加。該製劑暫時取代丟失的第八因子。通常情況下，蛋白質的存在有助於血液凝結和止血。這種藥物通常透過靜脈注射至少 5 到 10 分鐘，或按照醫生的指示注射。可能需要隨著時間的推移緩慢地給藥，這取決於劑量和患者的反應。

全球抗血友病因子藥物市場概況

推動市場成長的主要因素是人口中罕見疾病病例的增加。此藥用於抑制和預防血液凝血因子 VIII 水平低下（血友病 A）患者的出血發作。它也用於這些患者手術前的止血。血液凝固因子 VIII 水平正常的個體在受傷/手術後或內出血的風險會增加。本品含人體凝血因子VIII，又稱抗血友病因子。本產品暫時取代缺失的第八因子（第八因子為血液中正常存在的蛋白質），有助於血液凝結和止血。民眾對這些罕見疾病認識的提高以及政府參與預防和管理這些危及生命的疾病是推動抗血友病藥物市場預計成長的主要因素。此外，各大製藥公司對血友病新療法研發的投入不斷增加，推動著市場的快速擴張。

儘管透過對捐血者的仔細篩檢、專有製造流程和大量測試來降低這種風險，但這種藥物的感染風險很小，限制了抗血友病因子藥物市場的成長。

目錄

第1章 全球抗血友病因子藥物市場簡介

  • 市場概要
  • 調查範圍
  • 前提條件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的調查手法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源一覽

第4章 抗血友病因子藥物的全球市場展望

  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力分析
  • 價值鏈分析

第5章 抗血友病因子藥物的全球市場:各產品

  • 概要
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • 其他

第6章 抗血友病因子藥物的全球市場:各用途

  • 概要
  • 成人
  • 兒童

第7章 抗血友病因子藥物的全球市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 全球其他地區
    • 南美
    • 中東·非洲

第8章 全球抗血友病因子藥物市場競爭情形

  • 概要
  • 各公司的市場排行榜
  • 主要的開發策略

第9章 企業簡介

  • Bayer
  • Shire
  • Novo Nordisk
  • Pfizer
  • Grifols
  • CSL Behring
  • Sanofi
  • Cigna
  • Octapharma
  • GC Pharma

第10章 相關報告相關報告

簡介目錄
Product Code: 14401

Antihemophilic Factor Drug Market Size and Forecast

Antihemophilic Factor Drug Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Antihemophilic factor drug is used to treat and control severe bleeding spells in patients with a bleeding problem. Increasing awareness among people and growing rare disorders among people across the globe is a significant problem for the healthcare field is the factor driving the market growth of the Antihemophilic Factor Drug Market. The Global Antihemophilic Factor Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Antihemophilic Factor Drug Market Definition

Anti-hemophilia factor drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People with normal factor VIII levels are at increased risk of injury, post-surgery bleeding, and factor VIII bleeding in the body, also known as an anti-hemophilia factor. This product temporarily replaces lost factor VIII. A protein is usually present to help blood clots and stop bleeding. The medicine is usually given by intravenous injection for at least 5-10 minutes or as directed by the doctor. Depending on your dose and patient response, the drug may need to be given more slowly over time. After receiving this medicine for the first time at a hemophilia treatment center or hospital, some patients can self-administer this medicine at home. The drugs and solutions used for mixing were refrigerated. After adding the resolution to the powder, some brands of this drug may need to shake the vial for 10-15 seconds before gently rotating the vial to dissolve the powder completely. Ask your pharmacist about the correct combination of the medicines. Visually inspect for particulate matter or discoloration before using this product.

Global Antihemophilic Factor Drug Market Overview

The primary factor driving the market growth is the increasing number of rare disorder cases among people is the factor driving the market growth. This drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People at the general factor VIII level are at increased risk of injury / post-surgery and internal bleeding. This product contains Human Factor VIII, also known as an anti-hemophilia factor. This product temporarily replaces lost element VIII and a protein usually present in the blood to help blood clots and stop bleeding. Increasing awareness of such rare diseases among the population and government involvement in preventing and managing these life-threatening diseases are key factors behind the estimated growth of the antihemophilic drug market. In addition, increased investment by leading pharmaceutical companies in the research and development of new treatments for hemophilia is driving market expansion at an alarming rate.

Careful screening of blood donors, a unique manufacturing process, and many tests have been used to reduce this risk, but the risk of infection with this drug is minimal, limiting the market growth of the Antihemophilic factor Drug Market.

Global Antihemophilic Factor Drug Market: Segmentation Analysis

The Global Antihemophilic Factor Drug Market is segmented on the basis of Product, Application, and Geography.

Antihemophilic Factor Drug Market by Product

  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies

Based on Product, the market is segmented into 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU and Other potencies.

Antihemophilic Factor Drug Market by Application

  • Adult
  • Pediatric

Based on the Application, the Adult segment holds a large number of shares in the market because the low risk for hypersensitivity reactions increases cases of disorders in adult ages peoples, which is the factor that boosts the market growth of the Antihemophilic factor Drug Market.

Antihemophilic Factor Drug Market by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the North American region holds a large number of shares in the market because of the increasing number of cases in the region. The existence of key players in the region is the factor that propels the market growth of the Antihemophilic factor Drug Market.

Key Players

The "Global Antihemophilic Factor Drug Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are

Bayer, Shire, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, and GC Pharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 250 IU
  • 5.3 500 IU
  • 5.4 1000 IU
  • 5.5 1500 IU
  • 5.6 2000 IU
  • 5.7 3000 IU
  • 5.8 4000 IU
  • 5.9 Other potencies

6 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Adult
  • 6.3 Pediatric

7 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Bayer
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Shire
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Novo Nordisk
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Pfizer
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Grifols
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 CSL Behring
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Development
  • 9.7 Sanofi
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Cigna
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Octapharma
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Development
  • 9.10 GC Pharma
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Development

10 Related Reports